Affordable Access

deepdyve-link
Publisher Website

Immune checkpoint inhibitors and cardiovascular toxicity.

Authors
  • Lyon, Alexander R1
  • Yousaf, Nadia2
  • Battisti, Nicolò M L2
  • Moslehi, Javid3
  • Larkin, James2
  • 1 Cardio-Oncology Service, Royal Brompton Hospital, London, UK; National Heart and Lung Institute, Imperial College London, London, UK. Electronic address: [email protected]
  • 2 Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • 3 Cardiooncology Program, Vanderbilt School of Medicine, Nashville, TN, USA.
Type
Published Article
Journal
The Lancet. Oncology
Publication Date
Sep 01, 2018
Volume
19
Issue
9
Identifiers
DOI: 10.1016/S1470-2045(18)30457-1
PMID: 30191849
Source
Medline
Language
English
License
Unknown

Abstract

Immune checkpoint inhibitors are a new class of anticancer therapies that amplify T-cell-mediated immune responses against cancer cells. Immune checkpoint inhibitors have shown important benefits in phase 3 trials, and several agents have been approved for specific malignancies. Although adverse events from immune checkpoint inhibitors are a common occurrence, cardiotoxic effects are uncommon, but are often serious complications with a relatively high mortality. Most cardiotoxic effects appear to be inflammatory in nature. Clinical assessment of a combination of biomarkers, electrocardiography, cardiac imaging, and endomyocardial biopsy can be used to confirm a possible diagnosis. In this Review, we discuss the epidemiology of immune checkpoint inhibitor-mediated cardiotoxic effects, as well as their clinical presentation, subtypes, risk factors, pathophysiology, and clinical management, including the introduction of a new surveillance strategy. Copyright © 2018 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times